A phase 1/2 study of a first-in-human immune-stimulating antibody conjugate (ISAC) BDC-1001 in patients with advanced HER2-expressing solid tumors Meeting Abstract
| Authors: | Li, B. T.; Pegram, M. D.; Lee, K. W.; Sharma, M.; Lee, J.; Spira, A. I.; Hanna, G. J.; Kang, Y. K.; Rasco, D. W.; Moore, K. N.; Weinberg, B. A.; Alonso, M. N.; Ptacek, J.; Yin, M.; Tapia, .; Xu, Lu.; Perez, E. A.; Dumbrava, E. E. |
| Abstract Title: | A phase 1/2 study of a first-in-human immune-stimulating antibody conjugate (ISAC) BDC-1001 in patients with advanced HER2-expressing solid tumors |
| Meeting Title: | 2023 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 41 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2023 Jun 2-6 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2023-06-01 |
| Language: | English |
| DOI: | 10.1200/JCO.2023.41.16_suppl.2538 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| DOI/URL: | |
| Notes: | Meeting Abstract: 2538 -- This meeting was also held virtually -- Source: Cinahl |
